Univariate analysis of survival predictors after referral to phase 1 clinic in patients with mutBRAF advanced cancer.

1Royal Marsden Hospital (RMH) 13 prognostic score is determined as follows: 0 points, normal lactate dehydrogenase (LDH), albumin ≥3.5 g/dL, a ≤2 metastatic sites; 1 point- LDH>upper limit of normal, albumin 2 metastatic sites. Patients with 0–1 points had a good RMH score, and patients with 2–3 points had a poor RMH score.2Includes patients treated with other agents (N = 11) as well as patients who never started on phase 1 trial (N = 13).3One patient of whom the exact date of diagnosis was not documented was excluded only from the univariate analysis comparing the OSref between patients who had a time from diagnosis to metastasis less or more than 2 years.4Patients who never had a restaging at the last follow-up or who never started on a phase 1 trial were excluded in the univariate analysis (N = 22).